Intraoperative Radiation Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Intraoperative Radiation Therapy Devices, Intraoperative Radiation Therapy Accessories, and Software and Services), By Method (Electron, Intraoperative Brachytherapy, High Dose-Rate, X-Ray, Others), By Application (Breast Cancer, Brain Tumor, Head and Neck Cancer, Soft Tissue Sarcoma, Pediatric Tumors, Gynecological Cancer, Genitourinary Cancers, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 56.22 Million
CAGR (2026-2031)	5.55%
Fastest Growing Segment	Breast Cancer
Largest Market	North America
Market Size (2031)	USD 77.74 Million

Market Overview

The Global Intraoperative Radiation Therapy Market will grow from USD 56.22 Million in 2025 to USD 77.74 Million by 2031 at a 5.55% CAGR. Intraoperative Radiation Therapy (IORT) is a targeted oncology technique that involves delivering a high dose of radiation directly to a tumor bed during surgery, immediately following the resection of the malignancy. The primary drivers supporting this market include the clinical ability to preserve healthy surrounding tissue and the significant reduction of treatment duration, often converting weeks of external therapy into a single operative session. This efficiency is critical as healthcare systems strive to manage the escalating demand for cancer care. According to the World Health Organization’s International Agency for Research on Cancer, in 2024, updated estimates highlighted the growing global burden with approximately 20 million new cancer cases recorded in 2022.

However, a significant challenge impeding market expansion is the substantial capital investment required for acquiring specialized radiation equipment and retrofitting operating rooms with necessary shielding. This financial barrier is further compounded by the stringent requirement for highly skilled multidisciplinary teams, including surgeons and physicists, to coordinate precisely within a sterile environment. These operational complexities, combined with inconsistent reimbursement policies in various international regions, limit the capacity of many healthcare facilities to adopt IORT technologies.

Key Market Drivers

The escalating global prevalence of cancer cases acts as a primary catalyst for the Global Intraoperative Radiation Therapy Market, necessitating more efficient and scalable treatment modalities. As patient volumes rise, healthcare systems are compelled to adopt therapies that reduce surgical backlogs and treatment duration, such as IORT, which delivers concentrated radiation in a single operative session. This demand is particularly acute in breast oncology, where the burden is expanding rapidly, driving the need for time-efficient breast-conserving interventions. According to the International Agency for Research on Cancer, February 2025, in a study published in 'Nature Medicine', it is projected that by 2050, the annual global incidence will reach 3.2 million new breast cancer cases if current trends persist. This rising trajectory underscores the urgent necessity for expedited therapeutic techniques like IORT to manage the growing patient population effectively.

Technological advancements in portable and miniaturized IORT systems further propel market growth by eliminating the need for expensive, shielded operating bunkers, thereby lowering substantial adoption barriers for hospitals. Modern mobile units allow for precise radiation delivery directly in standard operating rooms, enhancing workflow versatility and operational efficiency for providers. This shift towards accessible, mobile technology is reflected in the financial performance of key industry innovators who are successfully commercializing these solutions. According to Sensus Healthcare, February 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', the company reported a 71% increase in full-year revenue to $41.8 million, driven by the expanding adoption of its radiation therapy portfolio. Furthermore, the sustained investment capacity of major medical technology players continues to support this sector; according to Carl Zeiss Meditec AG, December 2025, in the 'Annual Report 2024/25', the group achieved a total revenue of €2,227.6 million, highlighting the robust industrial scale supporting the development of advanced oncological solutions.

Download Free Sample Report

Key Market Challenges

The substantial capital expenditure required for acquiring specialized equipment and retrofitting operating rooms stands as a formidable barrier to the growth of the Global Intraoperative Radiation Therapy Market. Healthcare facilities face significant upfront costs to install necessary shielding and procure high-tech radiation devices, which limits adoption primarily to large, well-funded academic centers. This restriction prevents widespread market penetration, as smaller hospitals often lack the budget to support such capital-intensive projects. Additionally, the operational complexity of coordinating highly skilled multidisciplinary teams within sterile environments adds to the resource burden, further deterring potential buyers.

This financial challenge is critically aggravated by declining reimbursement rates, which extend the return on investment period and reduce the economic viability of adopting new radiation technologies. According to the American Society for Radiation Oncology, in 2025, payment reductions for radiation oncology services under the Medicare Physician Fee Schedule have reached 25% since 2013. Such consistent decreases in financial support make it increasingly difficult for healthcare providers to justify the heavy investment needed for intraoperative systems, thereby directly stifling market expansion.

Key Market Trends

The Expansion of Clinical Applications to Neuro-Oncology and Gastrointestinal Cancers is significantly broadening the addressable patient base for the Global Intraoperative Radiation Therapy Market beyond its traditional stronghold in breast conservation. Medical device manufacturers are increasingly tailoring brachytherapy solutions to treat complex, deep-seated tumors such as glioblastomas and brain metastases, where precise, immediate radiation is crucial to prevent local failure. This shift is supported by compelling clinical efficacy data that encourages broader adoption in neurosurgical workflows. According to CancerNetwork, October 2025, in the 'Collagen Implant May Improve Local Control of Metastatic Brain Tumors' report, interim findings from the Phase 3 ROADS trial indicated that the use of GammaTile therapy reduced the risk of tumor recurrence or death by more than 50% compared to standard stereotactic radiotherapy in patients with newly diagnosed brain metastases.

Simultaneously, the Emergence of Robotic-Assisted Intraoperative Radiation Delivery is addressing the critical need for geometric precision when treating malignancies located near vital vascular structures. The integration of robotic positioning systems with radiation delivery devices allows oncologists to navigate difficult anatomical constraints, particularly in abdominal cancers, thereby maximizing dose conformity while sparing healthy tissue. This technological synergy is demonstrating remarkable improvements in local control rates for notoriously difficult-to-treat indications. According to News-Medical.net, October 2025, in the 'Preliminary study shows intraoperative radiation's success against pancreatic cancer spread' article, investigators at Johns Hopkins reported that utilizing a robotic device for targeted intraoperative radiation delivery effectively reduced the recurrence rate around the pancreas to just 5% in patients with locally advanced pancreatic cancer.

Segmental Insights

The breast cancer segment is projected to be the fastest-growing category in the global intraoperative radiation therapy market, driven by the increasing preference for breast-conserving surgery. This method enables the delivery of targeted radiation immediately after tumor removal, eliminating the need for prolonged external beam radiotherapy sessions. The expansion is further bolstered by approvals from regulatory bodies such as the U.S. Food and Drug Administration, which affirm the safety of these procedures. Consequently, the clinical demand for efficient, single-dose treatment options for early-stage breast cancer patients is fueling significant segmental progress.

Regional Insights

North America leads the global Intraoperative Radiation Therapy (IORT) market, supported by a robust healthcare infrastructure and extensive adoption of localized radiation treatments. This dominance is primarily driven by favorable reimbursement frameworks and rising cancer incidence rates, which fuel the demand for efficient therapeutic options. Furthermore, the U.S. Food and Drug Administration facilitates market expansion through rigorous yet supportive regulatory approvals for medical devices. The presence of established domestic manufacturers also strengthens the supply chain, ensuring widespread availability of these therapies across clinical settings in the region.

Recent Developments

• In April 2025, Carl Zeiss Meditec AG received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the INTRABEAM 700 system. This next-generation intraoperative radiation therapy (IORT) platform features a digital-first architecture and robotic-assisted precision, designed to improve workflow efficiency during cancer surgeries. The system enables the delivery of a targeted dose of radiation directly to the tumor bed immediately after excision, minimizing exposure to healthy surrounding tissue. The clearance of the INTRABEAM 700 represents a significant expansion of the company's oncology portfolio, offering neurosurgeons and breast surgeons an advanced tool for integrating radiation therapy directly into the surgical procedure.
• In September 2024, Varian Medical Systems, a Siemens Healthineers company, entered into a strategic collaboration with Sun Nuclear to integrate advanced quality management solutions into its radiotherapy ecosystem. The partnership focused on incorporating SunCHECK quality assurance software with Varian's treatment systems to ensure consistent and automated verification of radiation delivery. This collaboration specifically addressed the need for rigorous quality control in complex radiation procedures, including brachytherapy and other targeted therapies, ensuring that clinicians can maintain high safety standards while optimizing patient treatment plans through enhanced data interoperability and workflow automation.
• In June 2024, Elekta AB announced the launch of a new AI-assisted treatment planning module designed specifically for its brachytherapy solutions. This advancement was introduced to streamline clinical workflows by automating complex planning tasks, thereby reducing the time required to create precise radiation dose distributions. The integration of artificial intelligence into the planning system aims to improve consistency and accuracy in treatment delivery for indications such as gynecological and prostate cancers. This development underscores the company's commitment to enhancing the efficiency of brachytherapy, a critical modality within the broader scope of intraoperative and interventional radiation therapies.
• In April 2024, Perspective Therapeutics, Inc. completed the divestiture of its brachytherapy business unit to GT Medical Technologies, Inc. This strategic transaction included the transfer of assets related to Cesium-131 radiotherapeutic seeds, which are utilized in Surgically Targeted Radiation Therapy (STaRT) for treating brain tumors and other cancers immediately following surgical resection. By divesting these assets, Perspective Therapeutics aimed to realign its resources toward the development of its alpha-particle therapy portfolio, while GT Medical Technologies expanded its footprint in the intraoperative brachytherapy market, enhancing its ability to provide targeted radiation solutions such as GammaTile Therapy to patients.

Key Market Players

• IntraOp Medical, Inc
• iCAD, Inc.
• Elekta AB
• Sensus Healthcare, Inc.
• Isoray, Inc.
• Becton, Dickinson and Company
• Sordina IORT Technologies
• Varian Medical Systems, Inc.
• SeeDos Ltd.
• IsoAid LLC

By Product	By Method	By Application	By End User	By Region
Intraoperative Radiation Therapy Devices Intraoperative Radiation Therapy Accessories Software and Services	Electron Intraoperative Brachytherapy High Dose-Rate X-Ray Others	Breast Cancer Brain Tumor Head and Neck Cancer Soft Tissue Sarcoma Pediatric Tumors Gynecological Cancer Genitourinary Cancers Others	Hospitals & Clinics Ambulatory Care Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Intraoperative Radiation Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Intraoperative Radiation Therapy Market, By Product:

• Intraoperative Radiation Therapy Devices
• Intraoperative Radiation Therapy Accessories
• Software and Services

• Intraoperative Radiation Therapy Market, By Method:

• Electron
• Intraoperative Brachytherapy
• High Dose-Rate
• X-Ray
• Others

• Intraoperative Radiation Therapy Market, By Application:

• Breast Cancer
• Brain Tumor
• Head and Neck Cancer
• Soft Tissue Sarcoma
• Pediatric Tumors
• Gynecological Cancer
• Genitourinary Cancers
• Others

• Intraoperative Radiation Therapy Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

• Intraoperative Radiation Therapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE